Multimodal Approach of Pulmonary Artery Intimal Sarcoma: A Single-Institution Experience
Table 2
Main characteristics and outcomes of the patients.
Patients ()
Sex Age
Symptoms duration (months)
Symptoms
Date of diagnoses
Histologic type (differentiation)/grading
Site(s) of disease
IP (PAPS) mmHg
Treatment after surgery
Time from surgery to CT (days)
cycles of CT
Disease status
Overall survival (months)
1
F 45
9
Dyspnea Right cardiac failure
2010
IS (fibrosarcoma) G2
Local M+ (lung, kidney, nodes)
85
CT
10 months
NA
PD
26
2
F 65
2
Pain Cough
2011
IS (osteocondroid diff) G2
Local (bilateral)
45
CT
50
6
NED
55
3
M 32
9
Fever Pain Dyspnea
2012
IS (undiff) G3
Local (unilateral)
65
CT
22
6
PD
6
4
F 74
8
Dyspnea Pain
2012
IS (fibrous histiocytoma diff) G3
Local (unilateral)
—
CT
48
6
PD
8
5
F 77
7
Dyspnea Pain Cough Hemoptysis
2012
IS (mixofibrous diff) G2
Local M+ (lung)
>60
CT
69
2
PD
6
6
F 49
33
Dyspnea
2013
IS (leiomuscolar diff) G2
Local M+ (lung)
90
CT
42
5
NED
28
7
F 64
15
Dyspnea Pain Dysesthesia
2014
IS (undiff) G3
Local (bilateral)
45
CT/RT
30
4
NED
21
8
M 77
2
Dyspnea Pain
2015
IS (undiff) G3
Local (bilateral)
100
CT/RT
25
4
PR
11
9
F 49
2
Heart failure
2015
IS (undiff) G3
Local (bilateral)
45
CT/RT
36
4
NED
10
10
M 84
4
Dyspnea Pain
2015
IS (undiff) G2
Local (bilateral)
70
CT
44
4
PD
8
11
F 37
6
Dyspnea Hemoptysis
2016
IS (osteosarcoma diff) G3
Local (bilateral)
—
CT
30
4
NED
4
IS: intimal sarcoma; M+: metastatic disease; CT: chemotherapy (adriamycin and ifosfamide); RT: radiotherapy; NA: not applicable; PD: progressive disease; NED: not evidence of disease; PR: partial response. Patient died. CT was given at disease progression. The patient who died perioperatively was excluded.
